Enesi Pharma has announced the beginning of a partnership with US Biomedical Advanced Research and Development Authority’s (BARDA) DRIVe (Division of Research, Innovation, and Ventures), in order to develop new vaccines against influenza enabled by Enesi’s ImplaVax device and formulation technology.
The public-private partnership aims to provide a cost-effective technological innovation that improves vaccination uptake, coverage, compliance and preparedness and is part of DRIVe’s innovative health security technologies portfolio.
David Hipkiss, Enesi chief executive, commented: “We are extremely proud to have been selected by BARDA DRIVe for this partnership. The team at DRIVe has been incredibly supportive of Enesi and clearly recognise the need to revolutionize vaccine delivery as part of their mission to advance research and development of medical countermeasures against serious health security threats.
“This is the latest in a series of key strategic partnerships and represents the next step in our journey to make a tangible difference to global healthcare.”
Under the programme, Enesi will leverage its ImplaVax platform, combining a protective influenza vaccine with its simple and robust needle-free vaccine delivery system, enhancing the vaccine’s efficacy, thermal stability and rapid administration to a target population.
The platform could become a potentially disruptive technology not only for pandemic influenza, but for multiple vaccines, vaccination protocols, infectious diseases and biological threats.
